Tevogen Bio Holdings Inc. - Common Stock (NQ:TVGN)

0.2772 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist

Price and Volume

Volume	911
Open	0.2772
Bid (Size)	0.2780 (700)
Ask (Size)	0.2887 (100)
Prev. Close	0.2772
Today's Range	0.2772 - 0.2772
52wk Range	0.2301 - 1.670
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

January 30, 2026

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

January 29, 2026

From Tevogen Bio Inc

Via GlobeNewswire

Performance

YTD	-23.8%	-23.8%
1 Month	-12.9%	-12.9%
3 Month	-38.3%	-38.3%
6 Month	-69.8%	-69.8%
1 Year	-83.0%	-83.0%

More News

FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel

January 14, 2026

Via MarketMinute

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

January 12, 2026

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

December 22, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen CEO Donates Personal Shares to Support Local Fire Department

December 19, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock

December 11, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

December 09, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

November 14, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

November 05, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

November 03, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

October 29, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

October 15, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

September 25, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

September 23, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

September 19, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

September 10, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

September 09, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

September 08, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

September 04, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

September 03, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

August 27, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

August 26, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

August 25, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

August 22, 2025

From Tevogen Bio Inc

Via GlobeNewswire

Frequently Asked Questions

Is Tevogen Bio Holdings Inc. - Common Stock publicly traded?

Yes, Tevogen Bio Holdings Inc. - Common Stock is publicly traded.

What exchange does Tevogen Bio Holdings Inc. - Common Stock trade on?

Tevogen Bio Holdings Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Tevogen Bio Holdings Inc. - Common Stock?

The ticker symbol for Tevogen Bio Holdings Inc. - Common Stock is TVGN on the Nasdaq Stock Market

What is the current price of Tevogen Bio Holdings Inc. - Common Stock?

The current price of Tevogen Bio Holdings Inc. - Common Stock is 0.2772

When was Tevogen Bio Holdings Inc. - Common Stock last traded?

The last trade of Tevogen Bio Holdings Inc. - Common Stock was at 02/18/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.